Exploring the Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: Systematic Review and Meta-analysis

Overview

Journal Cytojournal

Date 2024 Apr 17

PMID 38628287

Authors

Jia Zhang

Xinhua Ding

Xiaoxiao Ding

Affiliations

Soon will be listed here.

Abstract

Objective: Multiple myeloma (MM) is a bone marrow cancer that profoundly affects plasma cells involved in the immune response. Myeloma cells alter the average production of cells in the bone marrow. Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy allows genetic modifications of an individual's T-cells to increase the expression of CARs used to identify and attach BCMA proteins to the malignant cells. Our main objective is to perform a systematic review and meta-analysis to explore the efficacy and safety of anti-BCMA CAR T-cell therapy for MM.

Material And Methods: We searched five databases, PubMed, CNKI, EMBASE, Cochrane, Web of Science, and CNKI, for studies published on anti-BCMA,CAR-T-cell treatment for MM. Inclusion criteria involved prospective single-arm studies either single or multi-center, in various MM phases and studies that reported anti-BCMA,CAR-T-cell treatment for MM. We excluded non-English publications and conference papers. All statistical analyses were performed in R software and Review Manager 5.4.1.

Results: Thirteen articles were included in the analysis. We found that the overall response survival complete response increase was statistically significant. Similarly, the reduction in cytokine release syndrome grades 3 and 4 and neurotoxicity after follow-up was statistically significant. However, the reduction in minimal residual disease negativity (MRDN) was not statistically significant.

Conclusion: Using anti-BCMA CAR T-cell therapy in MM was highly efficacious and safe in lowering the adverse outcomes and improving the survival outcomes, complete response, and overall response.

References

Ramos C, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O . Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016; 126(7):2588-96. PMC: 4922690. DOI: 10.1172/JCI86000. View

Zhou X, Rasche L, Kortum K, Danhof S, Hudecek M, Einsele H . Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies. Front Immunol. 2021; 11:620312. PMC: 7793717. DOI: 10.3389/fimmu.2020.620312. View

Norris J, Simpson B, Ball R, Freeman A, Kirkham A, Parry M . A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. Eur Urol. 2020; 79(3):325-326. DOI: 10.1016/j.eururo.2020.12.017. View

Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S . Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. Am J Hematol. 2022; 97(5):537-547. DOI: 10.1002/ajh.26486. View

Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly M . Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Haematol. 2017; 180(1):71-81. DOI: 10.1111/bjh.15003. View

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View

Brudno J, Maric I, Hartman S, Rose J, Wang M, Lam N . T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018; 36(22):2267-2280. PMC: 6067798. DOI: 10.1200/JCO.2018.77.8084. View

Garfall A, Stadtmauer E, Hwang W, Lacey S, Melenhorst J, Krevvata M . Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018; 3(8). PMC: 5931130. DOI: 10.1172/jci.insight.120505. View

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D . Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726-1737. PMC: 8202968. DOI: 10.1056/NEJMoa1817226. View

10.

Baumeister S, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi J . Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2018; 7(1):100-112. PMC: 7814996. DOI: 10.1158/2326-6066.CIR-18-0307. View

11.

Lin L, Cho S, Xing L, Wen K, Li Y, Yu T . Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2020; 35(3):752-763. PMC: 7785573. DOI: 10.1038/s41375-020-0951-5. View

12.

Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C . A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021; 11(3):e346. PMC: 7943908. DOI: 10.1002/ctm2.346. View

13.

Markmann C, Bhoj V . On the road to eliminating long-lived plasma cells-"are we there yet?". Immunol Rev. 2021; 303(1):154-167. DOI: 10.1111/imr.13015. View

14.

Yu B, Jiang T, Liu D . BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020; 13(1):125. PMC: 7499842. DOI: 10.1186/s13045-020-00962-7. View

15.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo V, Chu Y . Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Front Immunol. 2019; 10:1613. PMC: 6646459. DOI: 10.3389/fimmu.2019.01613. View

16.

Kotch C, Barrett D, Teachey D . Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019; 15(8):813-822. PMC: 7936577. DOI: 10.1080/1744666X.2019.1629904. View

17.

Tan J, Jia Y, Zhou M, Fu C, Tuhin I, Ye J . Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J Hematol Oncol. 2022; 15(1):39. PMC: 8974082. DOI: 10.1186/s13045-022-01244-0. View

18.

Qin C, Tian D, Zhou L, Shang K, Huang L, Dong M . Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023; 8(1):5. PMC: 9810610. DOI: 10.1038/s41392-022-01278-3. View

19.

Honikel M, Olejniczak S . Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022; 12(9). PMC: 9496564. DOI: 10.3390/biom12091303. View

20.

Yan L, Qu S, Shang J, Shi X, Kang L, Xu N . Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Cancer Med. 2020; 10(2):563-574. PMC: 7877347. DOI: 10.1002/cam4.3624. View